Acute myeloid leukemia, or AML, is the most common aggressive leukemia affecting adults, with around 1,200 Australians diagnosed with AML each year. AML develops quickly, requiring treatment so swiftly – within just days of diagnosis, giving patients very little time to digest the news.
Clinical hematologist Dr Yin Yuan said patients may present out of the blue and experience little symptoms. “They can suddenly feel unwell for a short time and need to be admitted to hospital that night,” Dr Yuan said. “For patients, it’s a whirlwind, upturning their lives.”
Dr Yuan recently completed a PhD at the WEHI in the Roberts and Wei Laboratories, during which she investigated novel therapies for AML.
AML begins in the bone marrow
“It all starts in the bone marrow, which is like a factory,” explains Dr Yuan. “In a normal bone marrow, stem cells produce mature blood cells — red cells that carry oxygen, platelets that help the blood clot, and white cells that fight infection. AML, abnormal immature “blast” cells accumulate and do not develop into healthy cells. The blast cells grow quickly and overtake the ‘factory’, meaning the body can no longer make heathy blood cells.”
Rapidly-growing “blast” cells introduce health complications
Low levels of healthy blood cells can cause potentially life-threatening problems. Low red cells means vital organs can be starved of oxygen, low platelets can lead to bleeding, and low white cells means patients are at risk of severe infections. Sometimes the “blast” cells grow so quickly that they rapidly flood the bloodstream, which can block normal blood flow to important organs like the brain and lung. Because of these complications, AML is often considered a medical emergency.
Two treatment pathways and others in the works
For people with AML, there are currently two main treatment pathways.
Younger patients who have good organ function are treated with intensive chemotherapy. This usually involves about 4 weeks in hospital for the first cycle of treatment. This is because the chemotherapy clears the leukemic cells, but also affects normal blood cells, so patients need regular blood transfusions and antibiotics to help fight infection until their normal cells recover.
Dr Yuan explains: “The goal of this initial cycle of treatment is to clear out the majority of leukaemic cells.
“When we can no longer see leukaemia cells under the microscope, we call this ‘remission’.
However, we know that there is still low-level leukaemia remaining, so patients usually receive another 3-4 cycles of ‘consolidation’ chemotherapy.”
Some AML subtypes associated with higher risk of relapse
Certain subtypes of AML are associated with higher risk of relapse. For these patients, they may need a stem cell transplant. A stem cell transplant involves the patient’s own bone marrow being cleared out and replaced with donor marrow. Donor T cells (a type of immune cell) then ‘patrol’ for residual leukemia cells. In terms of donors, this may be a sibling (1 in 4 for a 100% match), a parent or child (guaranteed 50% match), or may be sourced from volunteer donors.
Stem cell transplants involve patients being inpatients for one month, and a further two months as outpatients. Mortality risk is significant, as is long term complications.
Major inroads: ‘non-intensive’ therapy for older patients
With the median age of AML diagnosis at 68, a significant proportion of patients are older and unable to tolerate high dose chemotherapy regimens. These patients receive a less intensive, targeted therapy, a combination of two drugs called venetoclax and azacitidine.
“Whilst we call this ‘non-intensive’ therapy, it is important to note that there are still significant side effects, and patients often still require admission to hospital for several weeks for the initial cycle, and require frequent hospital visits for ongoing cycles,” explains Dr Yuan.
Approximately two-thirds of patients achieve remission with this therapy, with an average survival of around 12 months.
“While not curative, it represents a major step forward for a group of patients that, a decade ago, had no meaningful options for treatment,” says Dr Yuan.
Some older people in good health can still continue on to receive a stem cell transplant.
Venetoclax is a targeted drug that works specifically against one weakness of the cancer cell, a protein called BCL-2.
Venetoclax is the result of a research collaboration between WEHI and companies Roche, Genentech (a member of the Roche Group) and AbbVie, and is based on groundbreaking scientific discoveries made at the institute over three decades. It was developed by Roche, Genentech and AbbVie.
The anti-cancer drug is based on a discovery made at WEHI in the late 1980s, that a protein called BCL-2 helps cancer cells survive indefinitely.
Venetoclax was first tested and approved for another blood cancer called chronic lymphocytic leukaemia (CLL) and later found the be effective also in AML. Current researchers at WEHI are trying to find ways to augment venetoclax efficacy and overcome resistance.
Targeting difficult-to-treat AML with a new class of drugs: STING agonists
There are some forms of AML that respond especially poorly to available treatments. The most lethal form of AML carries a mutation in the gene TP53.
“In cases of AML with TP53 mutations, essentially all existing therapies don’t work. Fewer than 10% of people diagnosed with TP53-mutated AML are alive two years after diagnosis.”
Gene mutation and a cell’s normal ‘shutdown’
“What happens is when the tumour-suppressive gene TP53 mutates, the cell’s normal ‘shut-down’ mechanisms fail.”
“TP53 is known as the ‘guardian of the genome’ – when it detects a cell being damaged, it pauses the cell from dividing and tells it to fix the broken DNA. Or, if the damage is too severe to fix, it forces the cell to undergo programmed cell death (apoptosis). When TP53 is mutated, this ‘safety inspector’ is lost. Most of our current anti-cancer treatments rely on normal TP53 function to work properly, which is why they are ineffective against TP53 mutated AML.”
This is the problem that Dr Yuan is currently tackling.
A new approach: STING agonists
Dr Yuan, together with collaborators in the Blood Cells and Blood Cancer Division at WEHI have been working on a new class of drugs known as STING agonists.
STING agonists have been studied in other cancers as a form of immune therapy (enhancing the body’s own anti-cancer immune response). However, Dr Yuan’s work found that STING agonists could directly kill AML blasts by causing them to undergo a form of programmed cell death known as apoptosis. This is the same mechanism that venetoclax works by. AML blasts have a unique vulnerability to STING agonists because they express much higher levels of STING compared with other cancer types.
STING agonists were first tested in vitro.
“It was found that STING agonists could very effectively kill laboratory AML cell lines and leukemia cells obtained from patients in vitro, alone and when combined with venetoclax,” explains Dr Yuan.
“Testing on real patient samples was an important step because laboratory cell lines can change in the artificial conditions of the lab and no longer reflect true human disease, whereas patient cells provide a much more accurate test of how the drug will handle diverse, real-world biology.”
Following this, in vivo testing was conducted to see how STING agonists performed in a living organism.
“This advanced testing was essential because a living body is much more complex than a lab dish, ensuring that the drug can safely travel through the blood stream, reach the bone marrow, and still destroy the cancer cells. We used a patient-derived xenograft model- implanting patient leukaemia cells into mouse models. Again, STING agonists alone and in combination with venetoclax was very effective, including in highly aggressive models.”
“STING agonists, combined with venetoclax, show a synergistic effect with the potential to overcome venetoclax resistance, including in TP53-defective AML,” says Dr Yuan.
“The next question we are asking these findings would translate to human patients.”
Upcoming phase 1 clinical trial: testing a new STING agonist alone and in combination with venetoclax
Dr Yuan and colleagues are now planning to test a new STING agonist alone and in combination with venetoclax in a phase 1 clinical trial. The trial will enroll patients with AML whose leukemia has returned or resisted normal treatments, and who have run out of standard therapy options. The goal of the trial is to find out if STING agonists can be safely delivered, and to determine the optimal dose to give. The trial is anticipated to open in Australia in 2027.
Read more decades of BCL-2 research here:
https://www.wehi.edu.au/about/history/leukaemia-clinical-trials/
Watch a video about apoptosis, a type of cell death that removes diseased and unwanted cells from the body:
https://www.wehi.edu.au/wehi-tv/apoptosis-and-venetoclax/
Dr Yin Yuan acknowledges funding by the Australian Government National Research Council (NHMRC; GNT2012234), the RCPA Foundation and Tour de Cure.








